EBGLYSS (lebrikizumab-lbkz) monotherapy achieved its primary endpoint in the Phase 3b ADtouch trial, with over half of patients showing clear or almost clear skin on hands and feet by Week 16. The treatment also provided significant itch and pain relief as early as two weeks, improving quality of life for those with moderate-to-severe hand and foot atopic dermatitis. Patient satisfaction was high, with nearly 80% satisfied with hand clearance. Eli Lilly plans to submit these results to regulatory authorities for potential label updates, reinforcing EBGLYSS as an effective biologic option for localized atopic dermatitis.
Eli Lilly's stock price is currently USD 1,185.40 on Pluang as of Sep 30, 2026 19:17 WIB, showing a slight 0.06% decrease in the last day. The company's market cap stands at $1.06 trillion, reflecting its significant presence in the health sector. Investor interest remains strong with 76% of Pluang order activity in buying positions, indicating confidence in Lilly's ongoing developments.
Novo Nordisk's analysis of real-world data shows that patients who switched from obesity injections like Wegovy or Lilly's Zepbound to Novo's new Wegovy pill continued to lose weight, shedding about 4% of their body weight on average after three mont...
Eli Lilly is growing faster than any other large drugmaker, driven by strong sales of Mounjaro and new FDA approvals for cardiovascular risk reduction and insulin products. The company plans to seek approval for retatrutide in early 2027, a drug show...
Navitas Semiconductor's shares rose 12% premarket after securing a U.S. Army contract to develop next-generation silicon carbide power semiconductor technology. This project aims to create a domestic manufacturing process for ultra-high-voltage silic...
Eli Lilly's Foundayo (orforglipron) 17.2 mg showed significantly greater weight loss (1.5% more) and A1C reduction (0.3% more) than oral semaglutide 25 mg after 52 weeks in adults with type 2 diabetes, based on an indirect comparison of ACHIEVE-3 and...
Eli Lilly launched the 'Change the Course Commitment' aiming to treat as many diabetes and obesity patients in low- and middle-income countries (LMICs) as in high-income countries by 2040. Currently, only one in four patients in LMICs have access to ...
